Agenus Inc.Long
AGEN - LONG
Updated
AGEN, a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11th.
What are they working on?:
Agenus is focusing on immuno-oncology, conducting Phase 2 trials with botensilimab in melanoma, MSS colorectal cancer (with balstilimab), and pancreatic cancer (with chemotherapy). They're also developing balstilimab, a PD-1 inhibitor, across various cancers, including cervical cancer in Phase 2 trials. AGEN2373, an anti-CD137 agonist, is in Phase 1 trials for solid tumors, showcasing Agenus's commitment to advancing cancer treatments through innovative therapies
POSSIBLE SELL CLIMAX HERE.
If we break below, I will look for another Buy opportunity at the .63 area.
What are they working on?:
Agenus is focusing on immuno-oncology, conducting Phase 2 trials with botensilimab in melanoma, MSS colorectal cancer (with balstilimab), and pancreatic cancer (with chemotherapy). They're also developing balstilimab, a PD-1 inhibitor, across various cancers, including cervical cancer in Phase 2 trials. AGEN2373, an anti-CD137 agonist, is in Phase 1 trials for solid tumors, showcasing Agenus's commitment to advancing cancer treatments through innovative therapies
POSSIBLE SELL CLIMAX HERE.
If we break below, I will look for another Buy opportunity at the .63 area.
Note
according to 8k filing, Details about Agenus Inc.'s clinical milestones and other significant developments will be discussed with investors during a special shareholder meeting scheduled for April 3, 2024. This meeting will address the proposed reverse stock split and other relevant topics to the company's future and investment opportunities.Trade active
Snagged some more cheapies at $0.63. now sitting with my pole in the water.Trade active
Will Continue to accumulate at the low .55-.60 cent range, Agenus Inc. announced that the first preclinical data for BMS-986442 (AGEN1777) will be presented at the AACR Meeting in San Diego, CA, from April 5-10, 2024. BMS-986442 has shown superior immune activation both as a monotherapy and in combination with PD-(L)1 blockers, outperforming traditional TIGIT antibodies in non-clinical assays. This Fc-enhanced, bispecific antibody targets TIGIT and CD96 immune checkpoint receptors, utilizing Agenus’ proprietary Fc-engineering platform for novel mechanisms of action beyond current anti-TIGIT therapies. Dr. Dhan Chand, Vice President of Research, highlighted the potential of BMS-986442 to overcome the limitations faced by conventional TIGIT antibodies in clinical settings through its innovative approach.Trade active
Picked up some more here.Note
.53 cents
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.